Ipsen: Q1 organic growth reaches 5.5%

(CercleFinance.com) - Ipsen announced on Thursday that it had achieved a "solid performance" in its first quarter, despite an environment described as "particularly difficult" due to the health crisis.


The biopharmaceutical group this morning reported sales growth of 5.5% at constant exchange rates in the first three months of the year, reaching 658.5 million euros. Sales were up 0.6% as reported.

The company also reiterated its financial targets for the full year, based on the scenario of a "gradual" recovery in global activity following the crisis.

In this context, its total sales are expected to increase by at least 4% at constant exchange rates this year, with an operating margin that should exceed 30%, excluding the possible impact of additional investments in external innovation.


Copyright (c) 2021 CercleFinance.com. All rights reserved.